Core Insights - Amarin Corporation has transitioned to a fully partnered commercialization model across all international markets, which is expected to enhance its operational efficiency and market reach [1][3] - The Q3 2025 financial results indicate a positive trend with a 17% increase in total net revenue compared to Q3 2024, driven primarily by strong U.S. sales [4][6] - The company aims to achieve sustainable positive free cash flow by 2026, reflecting confidence in its strategic actions and operational improvements [1][4] Financial Performance - Total net revenue for Q3 2025 was $49.7 million, up from $42.3 million in Q3 2024, marking a 17% increase [4][6] - Product revenue, net increased by 16% to $48.6 million, primarily due to higher U.S. sales, which rose by 34% to $40.9 million [5][7] - Operating expenses decreased by 20% to $33.3 million, largely due to a restructuring plan implemented in June 2025 [9][12] Operating Metrics - The operating loss for Q3 2025 was $11.1 million, significantly improved from a loss of $25.2 million in Q3 2024, reflecting a 56% reduction [4][14] - The net loss for Q3 2025 was $7.7 million, compared to a net loss of $25.1 million in the same quarter of the previous year, indicating a 69% improvement [15][34] - Cash and investments at the end of Q3 2025 totaled $286.6 million, down from $305.7 million in Q3 2024 [15] Strategic Initiatives - The company has established partnerships with seven parties across nearly 100 countries to leverage regional expertise and infrastructure for the commercialization of VASCEPA/VAZKEPA [3][17] - Amarin is focused on enhancing shareholder value through strategic actions and is optimistic about its global business potential [3][4]

Core Insights - Amarin Corporation, in collaboration with HLS Therapeutics, will present scientific data on Icosapent Ethyl (IPE) at the Canadian Cardiovascular Congress (CCC) from October 23 to 26, 2025, emphasizing their commitment to advancing cardiovascular care [1][2] Group 1: Scientific Presentations - Data presented at CCC 2025 will highlight the clinical value of IPE for cardiometabolic conditions and explore the mechanistic effects of EPA on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist [2] - Featured abstracts include a poster presentation on the ENCORE study, which indicates that Icosapent Ethyl reduces cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome [2][3] - An oral presentation will discuss the effects of Icosapent Ethyl on the risk and duration of hospitalizations and death in the REDUCE-IT study [3] Group 2: Product Information - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising IPE, launched in the U.S. in January 2020 for high-risk patients with persistent cardiovascular risk despite statin therapy [7] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [7] - VASCEPA is approved and sold in multiple countries, including Canada, China, Australia, and various European nations under the brand name VAZKEPA [7]